Sarah Gooding

Headley Way
Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 42 publications

High-throughput monoclonal gammopathy community monitoring programme.

High-throughput monoclonal gammopathy community monitoring programme.

Journal: British journal of haematology
Published: July 23, 2025

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Journal: Blood
Published: July 21, 2025

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Journal: Blood
Published: July 21, 2025

Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways.

Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways.

Journal: Blood
Published: July 18, 2025

Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways.

Mezigdomide reverses T-cell exhaustion through degradation of IKZF1/IKZF3 and reinvigoration of cytokine production pathways.

Journal: Blood
Published: July 18, 2025

NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.

NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.

Journal: British journal of haematology
Published: April 17, 2025

ADAR1 in lenalidomide resistance: still immunomodulation?

ADAR1 in lenalidomide resistance: still immunomodulation?

Journal: Blood
Published: March 13, 2025

comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders.

comBO: A combined human bone and lympho-myeloid bone marrow organoid for preclinical modeling of hematopoietic disorders.

Journal: Cell stem cell
Published: March 03, 2025

Quantitative liver function imaging and whole genome sequencing - Effective modalities for a new era in personalised decision-making for operable colorectal liver metastases?

Quantitative liver function imaging and whole genome sequencing - Effective modalities for a new era in personalised decision-making for operable colorectal liver metastases?

Journal: HPB : the official journal of the International Hepato Pancreato Biliary Association
Published: October 17, 2024

Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study.

Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study.

Journal: EJHaem
Published: September 03, 2024

Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond.

Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond.

Journal: Haematologica
Published: April 19, 2024

Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.

Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.

Journal: Haematologica
Published: September 17, 2023
Showing 1-12 of 42

Last Updated: 09/26/2026